-
Ethnicity also influences the clinical heterogeneity of mixed connective tissue disease of childhood onset: The French West Indies experience Autoimmun. Rev. (IF 13.6) Pub Date : 2024-03-05 Arthur Felix, Fabienne Louis-Sidney, Christophe Deligny, Benoit Suzon
-
Herpes vaccine, splenectomy, and thymectomy associated with autoimmune diseases and the kaleidoscope of autoimmunity Autoimmun. Rev. (IF 13.6) Pub Date : 2024-02-20 Abihai Lucas Hernández, Ora Shovman, Pnina Langevitz, Yehuda Shoenfeld
-
Reprint of “Residual pain in rheumatoid arthritis: Is it a real problem?” Autoimmun. Rev. (IF 13.6) Pub Date : 2024-01-24 Piercarlo Sarzi-Puttini, Margherita Zen, Federico Arru, Valeria Giorgi, Ernest A. Choy
Pain is a significant issue in rheumatoid arthritis (RA) and can have a negative impact on patients' quality of life. Despite optimal control of inflammatory disease, residual chronic pain remains a major unmet medical need in RA. Pain in RA can be secondary to inflammation but can also generate neuroendocrine responses that initiate neurogenic inflammation and enhance cytokine release, leading to
-
Corrigendum to “Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus – A proposal from an expert panel” [Autoimmunity Reviews, Volume 22, Issue 12, December 2023, 103479] Autoimmun. Rev. (IF 13.6) Pub Date : 2024-01-18 Ricardo Rojo, Jaime Calvo Alén, Álvaro Prada, Santiago Valor, Garbiñe Roy, Marcos López-Hoyos, Ricard Cervera, Paloma Sánchez Mateos, Aurora Jurado Roger
-
Childhood mixed connective tissue disease at disease onset: Evidence from a systematic review Autoimmun. Rev. (IF 13.6) Pub Date : 2024-01-06 Alberto Terminiello, Edoardo Marrani, Ilaria Pagnini, Ilaria Maccora, Valerio Maniscalco, Sarah Abu Rumeileh, Maria Vincenza Mastrolia, Gabriele Simonini
Objective Childhood Mixed Connective Tissue Disease (cMCTD) is the rarest pediatric connective tissue disease that includes features of systemic lupus erythematosus, polymyositis/dermatomyositis, juvenile idiopathic arthritis, and systemic sclerosis, identified by Sharp in 1972 and whose diagnosis remains challenging. This systematic review aims to identify clinical features at the onset of cMCTD and
-
Animal models unraveling the complexity of vitiligo pathogenesis Autoimmun. Rev. (IF 13.6) Pub Date : 2024-01-05 Prashant Giri, Dharm Desai, Mitesh Dwivedi
Vitiligo is a chronic skin condition marked by the gradual loss of pigmentation, leading to the emergence of white or depigmented patches on the skin. The exact cause of vitiligo remains not entirely understood, although it is thought to involve a blend of genetic, autoimmune, and environmental factors. While there is currently no definitive cure for vitiligo, diverse treatments exist that may assist
-
Benign prostatic hyperplasia - A novel autoimmune disease with a potential therapy consequence? Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-31 Victoria Liedtke, Michael Stöckle, Kerstin Junker, Dirk Roggenbuck
Benign prostatic hyperplasia (BPH) is considered as an age-related disease of men with an unknown etiopathophysiology. Chronic inflammation has been proposed as one of the major pathophysiological mechanisms. There is growing evidence for the involvement of autoimmune responses in an inflammatory setting in the prostate. Patients with autoimmune diseases show a significantly elevated prevalence of
-
Idiopathic and connective tissue disease-associated pulmonary arterial hypertension (PAH): Similarities, differences and the role of autoimmunity Autoimmun. Rev. (IF 13.6) Pub Date : 2024-01-03 Elvira Favoino, Marcella Prete, Vasiliki Liakouli, Patrizia Leone, Adriana Sisto, Luca Navarini, Marta Vomero, Francesco Ciccia, Piero Ruscitti, Vito Racanelli, Roberto Giacomelli, Federico Perosa
Pre-capillary pulmonary arterial hypertension (PAH) is hemodynamically characterized by a mean pulmonary arterial pressure (mPAP) ≥ 20 mmHg, pulmonary capillary wedge pressure (PAWP) ≤15 mmHg and pulmonary vascular resistance (PVR) > 2. PAH is classified in six clinical subgroups, including idiopathic PAH (IPAH) and PAH associated to connective tissue diseases (CTD-PAH), that will be the main object
-
Deciphering the clinical significance of longitudinal antiphospholipid antibody titers Autoimmun. Rev. (IF 13.6) Pub Date : 2024-01-01 Cecilia B. Chighizola, Rohan Willis, Gabriella Maioli, Savino Sciascia, Laura Andreoli, Olga Amengual, Massimo Radin, Maria Gerosa, Tatsuya Atsumi, Guilherme de Jesus, Laura Trespidi, D. Ware Branch, Roberto Caporali, Danieli Andrade, Robert Roubey, Michelle Petri, Maria Laura Bertolaccini
In antiphospholipid syndrome (APS), the risk of clinical manifestations increases with higher titers of antiphospholipid antibodies (aPL). Despite the adoption of aPL titers in the classification approach to aPL-positive subjects, the value of longitudinal monitoring of those titers in the follow-up is still debated, being well studied only in systemic lupus erythematosus (SLE). The literature suggests
-
Serum biomarkers and their relationship to axial spondyloarthritis associated with inflammatory bowel diseases Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-31 L. Ondrejčáková, M. Gregová, K. Bubová, L. Šenolt, K. Pavelka
Spondyloarthritis (SpA) constitute a group of chronic inflammatory immune-mediated rheumatic diseases characterized by genetic, clinical, and radiological features. Recent efforts have concentrated on identifying biomarkers linked to axial SpA associated with inflammatory bowel disease (IBD), offering predictive insights into disease onset, activity, and progression. Genetically, the significance of
-
Autoimmune response after SARS-CoV-2 infection and SARS-CoV-2 vaccines Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-29 Altijana Hromić-Jahjefendić, Kenneth Lundstrom, Muhamed Adilović, Alaa A.A. Aljabali, Murtaza M. Tambuwala, Ángel Serrano-Aroca, Vladimir N. Uversky
The complicated relationships between autoimmunity, COVID-19, and COVID-19 vaccinations are described, giving insight into their intricacies. Antinuclear antibodies (ANA), anti-Ro/SSA, rheumatoid factor, lupus anticoagulant, and antibodies against interferon (IFN)-I have all been consistently found in COVID-19 patients, indicating a high prevalence of autoimmune reactions following viral exposure.
-
Metal-induced autoimmunity in neurological disorders: A review of current understanding and future directions Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-28 Geir Bjørklund, Aleksandra Buha Đorđević, Halla Hamdan, David R. Wallace, Massimiliano Peana
Autoimmunity is a multifaceted disorder influenced by both genetic and environmental factors, and metal exposure has been implicated as a potential catalyst, especially in autoimmune diseases affecting the central nervous system. Notably, metals like mercury, lead, and aluminum exhibit well-established neurotoxic effects, yet the precise mechanisms by which they elicit autoimmune responses in susceptible
-
Comprehensive reproductive healthcare for women with immune-mediated inflammatory diseases: Addressing rheumatoid arthritis, spondyloarthritis and inflammatory bowel disease through life's stages Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-22 Laura Andreoli, Ilaria Guadagni, Giovanna Picarelli, Mariabeatrice Principi
Immuno-mediated inflammatory diseases (IMIDs) such as rheumatoid arthritis, spondyloarthritis, and inflammatory bowel disease are characterised by pathophysiological mechanisms wherein the immune system erroneously targets the body's own tissues. This review explores the heightened vulnerability of women with IMIDs, influenced by hormonal modulators like estrogen and progesterone. The challenges this
-
Pulmonary arterial hypertension associated with connective tissue diseases (CTD-PAH): Recent and advanced data Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-21 Benjamin Thoreau, Luc Mouthon
Pulmonary arterial hypertension (PAH), corresponding to group 1 of pulmonary hypertension classification, is a rare disease with a major prognostic impact on morbidity and mortality. PAH can be either primary in idiopathic and heritable forms or secondary to other conditions including connective tissue diseases (CTD-PAH). Within CTD-PAH, the leading cause of PAH is systemic sclerosis (SSc) in Western
-
Non-invasive imaging in antiphospholipid syndrome to assess subclinical coronary artery disease Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-20 Pamela Munguía-Realpozo, Claudia Mendoza-Pinto, Ivet Etchegaray-Morales, Juan Carlos Solis-Poblano, Karla Godinez-Bolaños, Mario García-Carrasco, Ricardo O. Escárcega, Socorro Méndez-Martínez, Luis Javier Jara-Quezada
Antiphospholipid antibody syndrome (usually named antiphospholipid syndrome, APS) is an autoimmune disorder seen mainly in young people. Clinically, APS is described by pregnancy complications and/or a hypercoagulable state, including the venous or arterial vasculature, and strongly related to antiphospholipid antibodies. Although several cardiac manifestations have been involved with APS, and accelerated
-
Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-20 Virginia Solitano, Paola Facheris, Magnus Petersen, Ferdinando D'Amico, Michela Ortoncelli, Daniel Aletaha, Pablo A. Olivera, Thomas Bieber, Sofia Ramiro, Subrata Ghosh, Maria Antonietta D'Agostino, Britta Siegmund, Isabelle Chary-Valckenaere, Ailsa Hart, Lorenzo Dagna, Fernando Magro, Renaud Felten, Paulo Gustavo Kotze, Vipul Jairath, Antonio Costanzo, Silvio Danese
Background and Aims The Pharmacovigilance Risk Assessment Committee (PRAC) proposed measures to address severe side effects linked to Janus kinase inhibitors (JAKi) in immune-mediated inflammatory diseases (IMID). Use of these medications in individuals aged 65 and older, those at high cardiovascular risk, active or former long-term smokers, and those with increased cancer risk should be considered
-
Adipose failure through adipocyte overload and autoimmunity Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-13 Nicola Susca, Patrizia Leone, Marcella Prete, Susanna Cozzio, Vito Racanelli
-
Combination of monoclonal antibodies targeting type 2 inflammation for severe asthma and eosinophilic granulomatosis with polyangiitis Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-13 Federica Davanzo, Maria Rita Marchi, Luca Iorio, Michela Bortoli, Andrea Doria, Roberto Padoan
Monoclonal antibodies targeting type 2 inflammation are promising treatments for eosinophilic-associated diseases. There is growing interest in the potential benefits of combining two biologics to treat patients with poorly controlled conditions. We present a case of a 54-year-old female patient affected with a relapsing-refractory ANCA myeloperoxidase positive eosinophilic granulomatosis with polyangiitis
-
Risks and outcomes of pregnancy in neuromyelitis optica spectrum disorder: A comprehensive review Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-05 Pakeeran Siriratnam, Saif Huda, Helmut Butzkueven, Anneke van der Walt, Vilija Jokubaitis, Mastura Monif
-
Dysfunction of the glymphatic system and sleep disturbance in rheumatoid arthritis and musculoskeletal pain: A gap related to pain becoming chronic Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-05 Isadora de Oliveira Barbosa, André Pontes-Silva, José Mário Prati
Abstract not available
-
Does a window of opportunity for rheumatoid arthritis-associated interstitial lung disease exist? Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-10 Mitsuhiro Akiyama, Waleed Alshehri, Yuko Kaneko
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammatory synovitis, eventually leading to joint destruction. Remarkable advancements in the emergence of molecular targeted therapies and the treatment strategy based on treat-to-target have made it possible for patients to lead their daily lives without disabilities. Specifically, early diagnosis and appropriate treatment
-
Machine learning application in autoimmune diseases: State of art and future prospectives Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-09 Maria Giovanna Danieli, Silvia Brunetto, Luca Gammeri, Davide Palmeri, Ilaria Claudi, Yehuda Shoenfeld, Sebastiano Gangemi
Autoimmune diseases are a group of disorders resulting from an alteration of immune tolerance, characterized by the formation of autoantibodies and the consequent development of heterogeneous clinical manifestations. Diagnosing autoimmune diseases is often complicated, and the available prognostic tools are limited. Machine learning allows us to analyze large amounts of data and carry out complex calculations
-
Vitamin D deficiency and non-infectious uveitis: A systematic review and Meta-analysis Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-03 William Rojas-Carabali, Juan Sebastián Pineda-Sierra, Carlos Cifuentes-González, María Sofía Morales, Paula Tatiana Muñoz-Vargas, Luisa Fernanda Peña-Pulgar, María Alejandra Fonseca-Mora, Danna Lesley Cruz, Ikhwanuliman Putera, Lucia Sobrin, Rupesh Agrawal, Alejandra de-la-Torre
Background Vitamin D plays a critical role in immunomodulation, and its deficiency is implicated in the pathogenesis of several autoimmune diseases. Nevertheless, its relationship with non-infectious uveitis (NIU), an inflammatory ocular disorder, remains inconclusive. Methods A systematic search was conducted in three databases from database inception until May 8, 2023, to investigate the potential
-
Global, regional, and national burden of inflammatory bowel disease and its associated anemia, 1990 to 2019 and predictions to 2050: An analysis of the global burden of disease study 2019 Autoimmun. Rev. (IF 13.6) Pub Date : 2023-12-03 Song Wang, Zhixia Dong, Xinjian Wan
Aim Inflammatory bowel disease (IBD) exhibited a global increase in incidence over the past decade. Understanding global burden of IBD can offer valuable insights for shaping future management strategies. We aimed to provide a comprehensive assessment of global burden of IBD from 1990 to 2019 and predictions to 2050. Methods Data on prevalence, incidence, Disability-Adjusted Life Years (DALYs), Years
-
-
From ASCA breakthrough in Crohn's disease and Candida albicans research to thirty years of investigations about their meaning in human health Autoimmun. Rev. (IF 13.6) Pub Date : 2023-11-30 Boualem Sendid, Marjorie Cornu, Camille Cordier, Julie Bouckaert, Jean Frederic Colombel, Daniel Poulain
Anti-Saccharomyces cerevisiae antibodies (ASCA) are human antibodies that can be detected using an enzyme-linked immunosorbent assay involving a mannose polymer (mannan) extracted from the cell wall of the yeast S. cerevisiae. The ASCA test was developed in 1993 with the aim of differentiating the serological response in two forms of inflammatory bowel disease (IBD), Crohn's disease and ulcerative
-
Invariant natural killer T cells in autoimmune cholangiopathies: Mechanistic insights and therapeutic implications Autoimmun. Rev. (IF 13.6) Pub Date : 2023-11-30 Roopa Hebbandi Nanjundappa, Kun Shao, Prasanna Krishnamurthy, M. Eric Gershwin, Patrick S.C. Leung, Channakeshava Sokke Umeshappa
Invariant natural killer T cells (iNKT cells) constitute a specialized subset of lymphocytes that bridges innate and adaptive immunity through a combination of traits characteristic of both conventional T cells and innate immune cells. iNKT cells are characterized by their invariant T cell receptors and discerning recognition of lipid antigens, which are presented by the non-classical MHC molecule
-
Relevance of vein wall thickness in Behcet's disease: A systematic review and meta-analysis Autoimmun. Rev. (IF 13.6) Pub Date : 2023-11-29 Mira Merashli, Tommaso Bucci, Jose Delgado-Alves, Paul R.J. Ames
Objectives To perform a meta-analysis on articles evaluating the common femoral vein wall thickness (VWT) in Behcet's disease and its possible clinical, laboratory and treatment correlates (BD). Methods Systematic search of EMBASE and PubMed databases from inception to October 2023; we employed random effect meta-analyses for continuous outcomes. Results The meta-analysis included 9 case-control and
-
Brain-regional characteristics and neuroinflammation in ME/CFS patients from neuroimaging: A systematic review and meta-analysis Autoimmun. Rev. (IF 13.6) Pub Date : 2023-11-26 Jin-Seok Lee, Wakiro Sato, Chang-Gue Son
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating condition characterized by an elusive etiology and pathophysiology. This study aims to evaluate the pathological role of neuroinflammation in ME/CFS by conducting an exhaustive analysis of 65 observational studies. Four neuroimaging techniques, including magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS)
-
Takotsubo syndrome occurring in systemic diseases: A French multicenter retrospective case-control study and literature review Autoimmun. Rev. (IF 13.6) Pub Date : 2023-11-26 Julien Culerrier, Benjamin Terrier, Matthieu Groh, Marilucy Lopez-Sublet, Benjamin De Sainte Marie, Géraldine Falgarone, Olivier Lidove, Patrick Mercie, Luc Mouthon, Christophe Meune, Robin Dhote
Objective Describe the characteristics of patients presenting with TTS during the course of a broad spectrum of systemic diseases, in comparison to classic TTS. Methods French multicenter retrospective case-control study completed by a literature review. Results 19 new cases were included in the study. The literature review identified 25 previously published cases. Among the 44 patients, 41 were females
-
Current knowledge on multiple sclerosis pathophysiology, disability progression assessment and treatment options, and the role of autologous hematopoietic stem cell transplantation Autoimmun. Rev. (IF 13.6) Pub Date : 2023-11-25 Georgios Gakis, Ioannis Angelopoulos, Ioannis Panagoulias, Athanasia Mouzaki
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that affects nearly 2.8 million people each year. MS distinguishes three main types: relapsing-remitting MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS). RRMS is the most common type, with the majority of patients eventually progressing to SPMS, in which neurological development is constant
-
New onset sarcoidosis following biologic treatment in patients with seronegative inflammatory arthritis: A case series and systematic literature review Autoimmun. Rev. (IF 13.6) Pub Date : 2023-11-24 Denise Donzella, Elisa Bellis, Paola Campisi, Gloria Crepaldi, Valeria Data, Paolo Dapavo, Claudia Lomater, Elena Marucco, Marta Saracco, Mariele Gatto, Annamaria Iagnocco
Objective To report cases of new onset sarcoidosis upon biologic (bDMARDs) treatment administration in patients with seronegative inflammatory arthritis in a real-life cohort, alongside a systematic literature review (SLR) on this topic. Methods We performed a retrospective analysis on clinical records of patients with seronegative arthritis followed up in a monocentric cohort who underwent bDMARDs
-
Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus – A proposal from an expert panel Autoimmun. Rev. (IF 13.6) Pub Date : 2023-11-13 Ricardo Rojo, Jaime Calvo Alén, Álvaro Prada, Santiago Valor, Garbiñe Roy, Marcos López-Hoyos, Ricard Cervera, Paloma Sánchez Mateos, Aurora Jurado Roger
-
Effects of cytotoxic T-lymphocyte-associated protein 4 compared to TNF inhibitors on lipid profile: Results from an observational multicentre rheumatoid arthritis cohort Autoimmun. Rev. (IF 13.6) Pub Date : 2023-11-11 Fabiola Atzeni, Fabio Cacciapaglia, James Galloways, Andreina Manfredi, Garifallia Sakellariou, Sam Norton, Elisa Gremese, Francesca Romana Spinelli, Ombretta Viapiana, Matteo Piga, Gian Luca Erre, Elena Bartoloni Bocci
Aim To evaluate the impact of selective cytotoxic T-lymphocyte-associated protein 4 (CTLA-4Ig) compared to tumor necrosis factor inhibitors (TNFi) on cardiovascular (CV) clinical and laboratory outcomes in patients with rheumatoid arthritis (RA). Methods We performed a prospective observational multicenter study of RA patients included in the “Cardiovascular Obesity and Rheumatic DISease (CORDIS)”
-
Serum calprotectin is a marker of disease activity in Giant cell arteritis Autoimmun. Rev. (IF 13.6) Pub Date : 2023-10-24 Antoine Saut, Marie-Hélène Paclet, Candice Trocmé, Bertrand Toussaint, Alexis Bocquet, Laurence Bouillet, Athan Baillet
Abstract not available
-
Anti-HMGCR immune-mediated necrotising myopathy: Addressing the remaining issues Autoimmun. Rev. (IF 13.6) Pub Date : 2023-10-24 Thomas Khoo, Hector Chinoy
The discovery of autoantibodies directed against the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) enzyme has defined a sub-set of immune-mediated necrotising myopathy (IMNM) which is strongly associated with exposure to statin medications. Although understanding of anti-HMGCR IMNM has grown considerably with the reporting of multiple cohorts in North America, Europe, Asia and Oceania, there remain
-
SLE classification criteria: Is “The causality principle” integrated and operative – and do the molecular and genetical network, on which criteria depend on, support the definition of SLE as “a one disease entity” – A theoretical discussion Autoimmun. Rev. (IF 13.6) Pub Date : 2023-10-24 Ole Petter Rekvig
Molecular and cellular aspects of the autoimmune pathophysiology in SLE is linked to the “The causality principle”. SLE Classification Criteria identify per definition disease measures (here: synonymous with classification criteria), but not diagnostic criteria within a classical framework. These two mostly theoretical criteria collections represent a salient conflict between phenomenology and the
-
Clinical features of dermatomyositis patients with anti-TIF1 antibodies: A case based comprehensive review Autoimmun. Rev. (IF 13.6) Pub Date : 2023-10-19 Ozgur C. Kilinc, Serdal Ugurlu
Background and objectives Dermatomyositis is chronic autoimmune disease primarily affecting skin and muscles. Antibodies are key players of pathogenesis and are in strong correlation with distinct clinical phenotypes. We present a case and a comprehensive review of the literature on dermatomyositis patients with Anti TIF1 antibodies. Methods PubMed and Web of Science databases were reviewed. 166 articles
-
Complement levels during the first trimester predict disease flare and adverse pregnancy outcomes in systemic lupus erythematosus: A network meta-analysis on 532 pregnancies Autoimmun. Rev. (IF 13.6) Pub Date : 2023-10-17 Massimo Radin, Irene Cecchi, Francesca Crisafulli, Evandro Mendes Klumb, Guilherme Ramires de Jesús, Marcela Ignacchiti Lacerda, Miguel Ángel Saavedra, Geraldine Vanessa Reyes-Navarro, Luca Iaccarino, Maddalena Larosa, Gabriella Moroni, Francesco Tamborini, Dario Roccatello, Laura Andreoli, Savino Sciascia, Cecilia Beatrice Chighizola
Background Complement levels have been proposed as candidate biomarkers of disease activity and obstetric risk in systemic lupus erythematosus (SLE) pregnancies, but their reliability has been questioned due to the physiologic fluctuations of complement during gestation. Thus, this network meta-analysis aimed at assessing the clinical significance of complement fluctuations in lupus pregnant women
-
A comprehensive review of the advances in neuromyelitis optica spectrum disorder Autoimmun. Rev. (IF 13.6) Pub Date : 2023-10-16 Pakeeran Siriratnam, Saif Huda, Helmut Butzkueven, Anneke van der Walt, Vilija Jokubaitis, Mastura Monif
Neuromyelitis optica spectrum disorder (NMOSD) is a rare relapsing neuroinflammatory autoimmune astrocytopathy, with a predilection for the optic nerves and spinal cord. Most cases are characterised by aquaporin-4-antibody positivity and have a relapsing disease course, which is associated with accrual of disability. Although the prognosis in NMOSD has improved markedly over the past few years owing
-
From inflammation to renal fibrosis: A one-way road in autoimmunity? Autoimmun. Rev. (IF 13.6) Pub Date : 2023-10-15 Dario Roccatello, Hui-Yao Lan, Savino Sciascia, Sanjeev Sethi, Alessia Fornoni, Richard Glassock
Renal fibrosis is now recognized as a main determinant of renal pathology to include chronic kidney disease. Deposition of pathological matrix in the walls of glomerular capillaries, the interstitial space, and around arterioles predicts and contributes to the functional demise of the nephron and its surrounding vasculature. The recent identification of the major cell populations of fibroblast precursors
-
Should we use nintedanib as early therapy in patients with SSc-ILD? Autoimmun. Rev. (IF 13.6) Pub Date : 2023-10-14 Elisabetta Zanatta, Beatrice Moccaldi, Gabriella Szucs, Paolo Spagnolo
Systemic sclerosis (SSc) is a heterogeneous autoimmune disease, where a significant proportion of patients develop interstitial lung disease (ILD), which is the major cause of mortality. In recent years, the diagnosis of SSc-ILD has improved a lot, and caring rheumatologists, together with pulmonologists, regularly screen and follow the development and course of ILD. Considerable progress has also
-
Aberrant N-myristoylation as a prelude to autoimmune manifestations in patients with SHOC2 mutations Autoimmun. Rev. (IF 13.6) Pub Date : 2023-10-02 Donato Rigante, Chiara Leoni, Roberta Onesimo, Valentina Giorgio, Valentina Trevisan, Giuseppe Zampino
Abstract not available
-
Idiopathic inflammatory myopathies – The burden of disease: Cohort analysis focusing on damage and comorbidities Autoimmun. Rev. (IF 13.6) Pub Date : 2023-09-29 Ana Campar, Inês Alves, Ana Martins da Silva, Fátima Farinha, Carlos Vasconcelos
Introduction/Background Idiopathic Inflammatory Myopathies (IIM) continue to be a major clinical challenge worldwide. The exact aetiopathogenesis of this chronic and disabling disease remains elusive, preventing the development of novel and effective therapeutic strategies and leading to a high incidence of damage. The complexity of treating these diseases is even greater due to the numerous comorbidities
-
Pursuing appropriateness in antiphospholipid antibodies testing: Feasibility study with a reflex test approach for anti-β2GPI I domain Autoimmun. Rev. (IF 13.6) Pub Date : 2023-09-22 Maria Infantino, Silvia Foddai, Mariangela Manfredi, Maurizio Benucci, Massimo Radin, Irene Cecchi, Alice Barinotti, Ofir Aluf, Elena Rubini, Rahbari Elnaz, Elisa Menegatti, Dario Roccatello, Savino Sciascia
Abstract not available
-
Low-dose intravenous immunoglobulin (IVIg) in different immune-mediated conditions Autoimmun. Rev. (IF 13.6) Pub Date : 2023-09-23 Maria Giovanna Danieli, Eleonora Antonelli, Stefania Auria, Elena Buti, Yehuda Shoenfeld
IVIg has been used for a long time as a replacement therapy for primary and secondary immunodeficiencies. Beside this supplementary role, when used at higher doses (i.e., 2 g/kg/monthly) it exerts an immunomodulatory role able to control multiple autoimmune and systemic inflammatory diseases. Several mechanisms of action have been described and hypothesized, nonetheless a synergistic action on the
-
Understanding, diagnosing, and treating Myalgic encephalomyelitis/chronic fatigue syndrome – State of the art: Report of the 2nd international meeting at the Charité Fatigue Center Autoimmun. Rev. (IF 13.6) Pub Date : 2023-09-22 Sophie Steiner, Annick Fehrer, Friederike Hoheisel, Simon Schoening, Anna Aschenbrenner, Nina Babel, Judith Bellmann-Strobl, Carsten Finke, Øystein Fluge, Laura Froehlich, Andreas Goebel, Bettina Grande, Johannes-Peter Haas, Bettina Hohberger, Leonard A. Jason, Anthony L. Komaroff, Eliana Lacerda, Max Liebl, Andrea Maier, Olav Mella, Carmen Scheibenbogen
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a devastating disease affecting millions of people worldwide. Due to the 2019 pandemic of coronavirus disease (COVID-19), we are facing a significant increase of ME/CFS prevalence. On May 11th to 12th, 2023, the second international ME/CFS conference of the Charité Fatigue Center was held in Berlin, Germany, focusing on pathomechanisms
-
Multiple sclerosis and pregnancy: Pathogenesis, influencing factors, and treatment options Autoimmun. Rev. (IF 13.6) Pub Date : 2023-09-21 Yinxiang Wang, Jue Wang, Juan Feng
-
Age-standardized incidence, prevalence, and mortality rates of autoimmune diseases in women of childbearing age from 1990 to 2019 Autoimmun. Rev. (IF 13.6) Pub Date : 2023-09-21 Fan Cao, Yi-Sheng He, Ni Sang, Yu-Chen Liu, Xiao Hu, Qin-Yu Ni, Li-Ming Tao, Sheng-Ping Hou, Zheng-Xuan Jiang, Hai-Feng Pan
Aim To estimate the age-standardized incidence, prevalence, and mortality rates of autoimmune diseases including rheumatoid arthritis (RA), inflammatory bowel disease (IBD), multiple sclerosis (MS), type 1 diabetes mellitus (T1DM), asthma, and psoriasis in women of childbearing age from 1990 to 2019, and to further analyze their changing trends, at global, regional, and national levels. Methods Women
-
Roles of interferon induced protein with tetratricopeptide repeats (IFIT) family in autoimmune disease Autoimmun. Rev. (IF 13.6) Pub Date : 2023-09-21 Yuan-Yuan Wu, Jun Xing, Xiao-Feng Li, Ying-Li Yang, Hua Shao, Jun Li
Interferon-induced tetrapeptide repeat (IFIT) family proteins are an important component of the antiviral immune response. There are four known members of the human IFIT family, namely IFIT1, IFIT2, IFIT3 and IFIT5. More and more evidence shows that IFIT family members are involved in a variety of pathophysiological processes in vivo, regulate the homeostasis and differentiation of a variety of cells
-
Immunoglobulins in systemic sclerosis management. A large multicenter experience Autoimmun. Rev. (IF 13.6) Pub Date : 2023-09-12 J. Tandaipan, A. Guillén-Del-Castillo, C.P. Simeón-Aznar, P.E. Carreira, C. De la Puente, J. Narváez, J. Lluch, M. Rubio-Rivas, J.J. Alegre-Sancho, G. Bonilla, C. Moriano, I. Casafont-Sole, R. García-Vicuña, V. Ortiz-Santamaría, E. Riera, B. Atienza-Mateo, R. Blanco, C. Galisteo, J.J. Gonzalez-Martin, J.M. Pego-Reigosa, I. Castellví
Objective To analyze the effectiveness and safety of intravenous immunoglobulin (IVIG) given in routine care to patients with systemic sclerosis (SSc). Methods A retrospective multicenter observational study was conducted in SSc patients treated with IVIG. We collected data on epidemiological parameters and clinical outcomes. Firstly, we assessed changes in organ manifestations during IVIG treatment
-
Breast implant illness: Is it causally related to breast implants? Autoimmun. Rev. (IF 13.6) Pub Date : 2023-09-13 Jan Willem Cohen Tervaert, Yehuda Shoenfeld, Claudio Cruciani, Carlotta Scarpa, Franco Bassetto
Once believed to be completely inert implants, Silicon Breast Implants (SBIs) have been shown to be able to induce a chronic inflammatory response in the body which can lead to a variety of possible manifestations ranging from the most common capsular contraction to rarer conditions such as malignancies and autoimmune diseases. Among the latter, new syndromes have been consistently recognized: Breast
-
Risk of venous thromboembolism in autoimmune diseases: A comprehensive review Autoimmun. Rev. (IF 13.6) Pub Date : 2023-09-14 Danilo Menichelli, Vito Maria Cormaci, Silvia Marucci, Giovanni Franchino, Francesco Del Sole, Alessandro Capozza, Alessia Fallarino, Emanuele Valeriani, Francesco Violi, Pasquale Pignatelli, Daniele Pastori
Autoimmune diseases have specific pathophysiologic mechanisms leading to an increased risk of arterial and venous thrombosis. The risk of venous thromboembolism (VTE) varies according to the type and stage of the disease, and to concomitant treatments. In this review, we revise the most common autoimmune disease such as antiphospholipid syndrome, inflammatory myositis, polymyositis and dermatomyositis
-
Is cyclophosphamide still the gold standard in early severe rapidly progressive systemic sclerosis? Autoimmun. Rev. (IF 13.6) Pub Date : 2023-09-09 Corrado Campochiaro, Yannick Allanore, Yolanda Braun-Moscovici, Marco Matucci Cerinic, Alexandra Balbir-Gurman
Cyclophosphamide (CYC) has been a gold standard of treatment for severe progressive Systemic Sclerosis (SSc), especially in patients with concomitant interstitial lung disease (ILD). This approach was based on results of several interventional studies, including randomized control trials, which mainly addressed SSc-ILD as a primary end point and skin involvement as a second one. The use of CYC is time-limited
-
Efficacy and safety of Janus kinase inhibitors in systemic and cutaneous lupus erythematosus: A systematic review and meta-analysis Autoimmun. Rev. (IF 13.6) Pub Date : 2023-09-09 Leyao Ma, Liying Peng, Jiuliang Zhao, Wei Bai, Nan Jiang, Shangzhu Zhang, Chanyuan Wu, Li Wang, Dong Xu, Xiaomei Leng, Qian Wang, Wen Zhang, Yan Zhao, Xinping Tian, Mengtao Li
Background Janus kinase (JAK) inhibitors have been proven to be effective and safe in various autoimmune diseases. However, there is still a lack of comprehensive evidence regarding their efficacy and safety in systemic and cutaneous lupus erythematosus. Methods We searched for systemic and cutaneous lupus erythematosus patients who were treated with JAK inhibitors in PubMed, Embase, Web of Science
-
SpA plus IBD or IBD plus SpA: Does commutative property apply? Autoimmun. Rev. (IF 13.6) Pub Date : 2023-09-09 Francesco Carubbi, Alessia Alunno, Angelo Viscido, Xenofon Baraliakos, Francesco Maria Mariani, Evy Di Ruscio, Piera Altieri, Claudio Ferri
The term spondyloarthritis (SpA) encompasses a group of interrelated disorders characterised by the involvement of the musculoskeletal system as well as extra-articular manifestations like acute anterior uveitis, psoriasis and inflammatory bowel diseases (IBD). Likewise, IBD may present with various extra-intestinal manifestations among which those involving the musculoskeletal system, namely peripheral
-
Paraneoplastic autoimmune Laminin-332 syndrome (PALS): Anti-Laminin-332 mucous membrane pemphigoid as a prototype Autoimmun. Rev. (IF 13.6) Pub Date : 2023-09-05 A. Razzaque Ahmed, Mikole Kalesinskas, Sarah Kooper-Johnson
Importance Laminin-332 is an important component of the basement membrane. Recently, autoantibodies to Laminin-332 have been described in several autoimmune diseases. Many of these autoimmune diseases have a high incidence of malignancy. The importance of Laminin-332 autoantibodies and its relationship to malignancy is highlighted by using Laminin-332 Pemphigoid (LM-332Pg) as a prototype. Objective
-
Is it safe to withdraw low-dose glucocorticoids in SLE patients in remission? Autoimmun. Rev. (IF 13.6) Pub Date : 2023-09-06 Alexis Mathian, Laurent Arnaud, Guillermo Ruiz-Irastorza
Glucocorticoids (GCs) remain a cornerstone of the treatment of Systemic Lupus Erythematosus (SLE). Numerous studies have emphasized the risk of damage accrual in SLE patient treated with GC, but currently, it is not possible to dissociate favorable and undesirable effects of GCs because their underlying mechanisms are entangled at the molecular level. Here, we review whether available data suggest
-
Severity of neurological Long-COVID symptoms correlates with increased level of autoantibodies targeting vasoregulatory and autonomic nervous system receptors Autoimmun. Rev. (IF 13.6) Pub Date : 2023-09-07 Felix S. Seibert, Ulrik Stervbo, Lea Wiemers, Sarah Skrzypczyk, Maximillian Hogeweg, Sebastian Bertram, Julia Kurek, Moritz Anft, Timm H. Westhoff, Nina Babel
-
Autoimmune lymphoproliferative syndrome: A disorder of immune dysregulation Autoimmun. Rev. (IF 13.6) Pub Date : 2023-09-06 Amy Paskiewicz, Jianli Niu, Christopher Chang
Autoimmune Lymphoproliferative Syndrome (ALPS) is an autoimmune disease that has been reported in over 2200 patients. It is a rare, genetic disease where pathogenic variants occur in the extrinsic pathway of apoptosis. Various mutations in different genes, such as FAS, FASL, and CASP10, can result in ALPS. Most commonly, pathogenic variants occur in the FAS receptor. This malfunctioning pathway allows